The CARE consortium is now closed. This website is no longer updated but will remain available until 31 March 2026

December 13th 2022
Call for collaboration

Possible collaboration with IMI CARE for late phase development of SARS-CoV-2/pan coronavirus antivirals and antibodies.

Have you developed a SARS-CoV-2 or potential broad-spectrum compound (small molecule or antibody) and need support with its characterisation, pre-clinical and/or early clinical testing? The CARE project has developed three platforms open to external collaboration to prepare the next generation of SARS-CoV-2/pan coronavirus antivirals/antibodies: an in vitro profiling platform, a pre-clinical in vivo platform and a clinical trial platform.

The CARE project is looking for promising SARS-CoV-2 and/or pan coronavirus antiviral compounds (small molecules and antibodies) to include in its pipeline. Although CARE is particularly interested in clinic ready assets, the project can also provide support for pre-clinical phase of development. CARE can help you with the development of your compound(s) by providing:

  • A clinical trial platform of five centres in Europe with experience in clinical trials in infectious disease. The CARE project focuses on phase 1 and phase 2a trials
  • Pre-clinical in vivo characterisation of small molecules and antibodies in hamster, mouse and non-human primate efficacy models against various SARS-CoV-2 variants.
  • A well-developed platform of in vitro assays (viral yeld assays, time of addition assays, assays to interrogate mode of action, etc.) for profiling of compounds(*) in different cell lines (e.g. VeroE6, A549, ex vivo broncheal and nasal epithelial cells) against different SARS-CoV-2 variants as well as other coronaviruses.
  • A platform for the assessment of the inhibitory properties of compounds (*) in target-based assays and the study of the interaction of compounds(*) with their target.

*Please note that compounds already screened via ISIDORe will not be accepted to avoid duplication of effort.

If you are interested, please contact us through the contact form: https://www.imi-care.eu/contact/

Download the call for collaboration here: Possible collaboration with IMI CARE for late phase development of SARS-CoV-2/pan coronavirus antivirals and antibodies.